U.S. License Holder:
Seagen
Date of License:
September-20-2021
Last Update:
Sep-30-2024
FDA-Approved Indications
TIVDAK (tisotumab vedotin-tftv) is a tissue factor-directed antibody and microtubule inhibitor conjugate indicated for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.